Oncology drugs are medications that are used to treat cancer. These drugs work by targeting and killing cancer cells or slowing down their growth and spread. The oncology drug market in China is a significant and rapidly growing market, driven by the increasing incidence of cancer in the country and the growing demand for effective cancer treatments. According to the latest research, the oncology drug market in China is poised to grow by USD 41.0 billion during 2023-2029, progressing at a CAGR of 12.46% during the forecast period. One of the key drivers of growth in the oncology drug market in China is the increasing incidence of cancer in the country. According to the National Cancer Center of China, the number of new cancer cases in China is expected to reach 4.5 million by 2025. This has led to a growing demand for effective cancer treatments and has created opportunities for pharmaceutical companies to develop and market new oncology drugs. Another factor driving growth in the oncology drug market in China is the increasing government support for cancer research and treatment. The Chinese government has launched several initiatives to improve cancer prevention, diagnosis, and treatment, and has increased funding for cancer research and development. In addition, the rise of precision medicine and targeted therapies has led to the development of new oncology drugs that are more effective and have fewer side effects compared to traditional chemotherapy. These drugs are designed to target specific cancer cells or genetic mutations, and are personalized to each patient’s unique cancer profile.

This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and product. The China market data on oncology drug can be segmented by type: breast, colorectum, liver, lung cancer, stomach, thyroid, others. Oncology drug market is further segmented by product: chemotherapy drugs, immunotherapy drugs, targeted drugs. Chemotherapy drugs was the highest contributor to the oncology drug market in China. Going forward, the immunotherapy drugs segment is projected to witness the highest CAGR during the forecast period.

The China oncology drug market is highly competitive. The oncology drug market is dominated by key players, which are AstraZeneca plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd., Novartis International AG, Roche Holding AG, Sanofi S.A., Taiho Pharmaceutical Co. Ltd. .

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
▹ Get a detailed picture of the China Oncology Drugs Market
▹ Identify segments/areas to invest in over the forecast period in the China Oncology Drugs Market
▹ Understand the competitive environment, the market’s leading players
▹ The market estimate for ease of analysis across scenarios in Excel format.
▹ Strategy consulting and research support for three months.
▹ Print authentication provided for the single-user license.